Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023 - Concepedia

Concepedia

Publication | Open Access

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

DOI Full Paper Access

568

Citations

26

References

2008

Year

Karen Kelly, Kari Chansky, Laurie E. Gaspar, Kathy S. Albain, James R. Jett, Yee Ung, Derick Lau, John J. Crowley, David R. Gandara

Journal of Clinical Oncology

Abstract

In this unselected population, gefitinib did not improve survival. Decreased survival was a result of tumor progression and not gefitinib toxicity.

References

	Year	Citations

Page 1